Literature DB >> 9075929

The N-terminus of Nef from HIV-1/SIV associates with a protein complex containing Lck and a serine kinase.

A S Baur1, G Sass, B Laffert, D Willbold, C Cheng-Mayer, B M Peterlin.   

Abstract

The Nef protein of human and primate lentiviruses is a key factor in HIV/SIV pathogenesis. Here we report that Nef associates with two different kinases, forming a multiprotein complex at the far N-terminus of the viral protein. One of the kinases was identified as Lck, whereas the second protein was found to be a serine kinase that phosphorylated Nef and Lck in vitro and could be discriminated from the serine kinase identified previously. The Nef-associated kinase complex (NAKC) was demonstrated in COS cells, in HIV-infected cells, and in vitro using recombinant Lck and Nef proteins. Deletion of a short amphipathic alpha-helix in the N-terminus, which was found to be conserved in all Nef proteins, inhibited association of the NAKC and significantly reduced virion infectivity.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9075929     DOI: 10.1016/s1074-7613(00)80331-3

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  53 in total

1.  HIV-1 Nef protein binds to the cellular protein PACS-1 to downregulate class I major histocompatibility complexes.

Authors:  V Piguet; L Wan; C Borel; A Mangasarian; N Demaurex; G Thomas; D Trono
Journal:  Nat Cell Biol       Date:  2000-03       Impact factor: 28.824

2.  Nef-induced major histocompatibility complex class I down-regulation is functionally dissociated from its virion incorporation, enhancement of viral infectivity, and CD4 down-regulation.

Authors:  H Akari; S Arold; T Fukumori; T Okazaki; K Strebel; A Adachi
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

3.  The Nef protein of HIV-1 associates with rafts and primes T cells for activation.

Authors:  J K Wang; E Kiyokawa; E Verdin; D Trono
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

4.  An arginine-faced amphipathic alpha helix is required for adenovirus type 5 e4orf6 protein function.

Authors:  J S Orlando; D A Ornelles
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

5.  E4orf6 variants with separate abilities to augment adenovirus replication and direct nuclear localization of the E1B 55-kilodalton protein.

Authors:  Joseph S Orlando; David A Ornelles
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

6.  Distinct trafficking pathways mediate Nef-induced and clathrin-dependent major histocompatibility complex class I down-regulation.

Authors:  S Le Gall; F Buseyne; A Trocha; B D Walker; J M Heard; O Schwartz
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

Review 7.  HIV-1 Nef control of cell signalling molecules: multiple strategies to promote virus replication.

Authors:  Alison L Greenway; Gavan Holloway; Dale A McPhee; Phoebe Ellis; Alyssa Cornall; Michael Lidman
Journal:  J Biosci       Date:  2003-04       Impact factor: 1.826

8.  cis expression of the F12 human immunodeficiency virus (HIV) Nef allele transforms the highly productive NL4-3 HIV type 1 to a replication-defective strain: involvement of both Env gp41 and CD4 intracytoplasmic tails.

Authors:  E Olivetta; K Pugliese; R Bona; P D'Aloja; F Ferrantelli; A C Santarcangelo; G Mattia; P Verani; M Federico
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

9.  Myristoyl moiety of HIV Nef is involved in regulation of the interaction with calmodulin in vivo.

Authors:  Mamoru Matsubara; Tao Jing; Kumi Kawamura; Naoshi Shimojo; Koiti Titani; Keiichiro Hashimoto; Nobuhiro Hayashi
Journal:  Protein Sci       Date:  2005-01-04       Impact factor: 6.725

10.  HIV-1 Nef inhibits ruffles, induces filopodia, and modulates migration of infected lymphocytes.

Authors:  Cinzia Nobile; Dominika Rudnicka; Milena Hasan; Nathalie Aulner; Françoise Porrot; Christophe Machu; Olivier Renaud; Marie-Christine Prévost; Claire Hivroz; Olivier Schwartz; Nathalie Sol-Foulon
Journal:  J Virol       Date:  2009-12-16       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.